Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test

Clinical Pharmacology and Therapeutics

Volumn 70, Issue 4, 2001, Pages 327-335

  Laine, K ^a   Tybring, G ^a   Hartter S ^a   Andersson, K ^a   Svensson, J O ^a   Widen J ^a   Bertilsson, L ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DEBRISOQUINE; NORTRIPTYLINE; PAROXETINE; SPARTEINE;

ADULT; ALLELE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DEPRESSION; DRUG EFFECT; DRUG METABOLISM; ENZYME METABOLISM; FEMALE; GENE DUPLICATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYDROXYLATION; MALE; MULTIGENE FAMILY; PRIORITY JOURNAL;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CYTOCHROME P-450 CYP2D6; DEBRISOQUIN; DRUG COMBINATIONS; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; HYPOTENSION, ORTHOSTATIC; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; NORTRIPTYLINE; PAROXETINE; PHENOTYPE; TREMOR; XEROSTOMIA;

EID: 0034751517     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.118523     Document Type: Article

References (28)

1. Polymorphic hydroxylation of debrisoquine
2. Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
3. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism
4. Polymorphic drug oxidation: Relevance to treatment of psychiatric disorders
5. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds
6. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
7. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis
8. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine
9. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone
10. Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County
11. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians
12. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles
13. Managing rapid metabolizers of antidepressants
14. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes
15. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients
16. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine
17. The relationship between paroxetine and the sparteine oxidation polymorphism
18. Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites
19. Rapid high-performance liquid chromatographic method for determination of debrisoquine and 4-hydroxy-debrisoquine in urine for CYP2D6 phenotyping
20. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification
21. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population
22. High-performance liquid chromatography-mass spectrometry for the quantification of nortriptyline and 10-hydroxynortriptyline in plasma
23. Relationship between plasma level and therapeutic effect of nortriptyline
24. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism
25. Time course of enzyme induction in humans: Effect of pentobarbital on nortriptyline metabolism
26. Stereoselective disposition of racemic E-10-hydroxynortriptyline in human beings
27. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence
28. Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients